Drug intelligence / Profile preview

IgA Shenbing Fang

Development stage: Preclinical
Administration: Oral

Overview

IgA Shenbing Fang (IgA肾病方) is a traditional Chinese medicine (TCM) formulation used in China for the treatment of IgA nephropathy (IgAN), also known as Berger disease. This formula is part of an integrative approach that combines TCM with Western medicine to manage symptoms and slow the progression of kidney damage in patients with IgAN. The specific herbal composition and mechanism of action are not standardized across all sources, but such formulas typically aim to reduce proteinuria, modulate immune responses, and protect renal function. Clinical studies suggest that combining Chinese herbal medicines like IgA Shenbing Fang with conventional therapies may offer better outcomes than either approach alone for some patients[4]. However, robust evidence from large-scale randomized controlled trials remains limited.

Other names: IgA肾病方

Beyond the preview

Go deeper on IgA Shenbing Fang.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IgA Shenbing Fang.

Explore the full profile